Inversago Pharma – The peripheral CB1 blockade company
Jan 31, 2024Clinical trial updates on INV-202 and INV-347 Aug 10, 2023Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases More news Our Approach ...